Metastatic Lung Adenocarcinoma Treatment Market was valued at USD 4.35 billion in 2023 and is expected to reach USD 11.58 billion by 2032, growing at a CAGR of 11.54% from 2024-2032.
This report provides information on the Metastatic Lung Adenocarcinoma Treatment Market based on important statistical data. The report presents incidence and prevalence rates for metastatic lung adenocarcinoma, with comprehensive insight into the disease burden. Further, the report reviews prescription trends globally, illustrating treatment choice and adoption rates. Our report also investigates patient volume undergoing treatment, highlighting therapeutic trend shifts. we provide healthcare expenditure distribution by government, commercial, private, and out-of-pocket sources, offering a monetary outlook on the accessibility and affordability of treatment. These findings inform strategic decision-making in the emerging treatment environment.
Drivers
The increasing adoption of targeted therapy and immunotherapy has significantly transformed the treatment landscape for metastatic lung adenocarcinoma.
The growing use of targeted therapy and immunotherapy has greatly altered the treatment pattern for metastatic lung adenocarcinoma. Targeted treatments, including EGFR, ALK, and KRAS inhibitors, offer precision therapy by targeting specific cancer-causing mutations. Immunotherapy agents like PD-1/PD-L1 inhibitors, including Bristol-Myers Squibb's Opdivo and Merck's Keytruda, have yielded incredible survival gains. As per a 2023 clinical trial, patients undergoing immunotherapy in combination with chemotherapy had a 30% greater overall survival rate than those undergoing chemotherapy alone. The FDA's February 2024 approval of AstraZeneca's Tagrisso in combination with chemotherapy further underscores the trend toward combination regimens. These developments have driven demand for novel treatment options, enhancing patient outcomes and fueling market growth. The growing number of clinical trials and biomarker-guided therapies keeps reinforcing the implementation of personalized medicine in metastatic lung adenocarcinoma.
Rising Incidence of Lung Cancer and Smoking-Related Cases is a key driver for market expansion.
The growing prevalence of lung cancer globally, especially metastatic lung adenocarcinoma, is one of the driving factors for market growth. Lung cancer, as projected by the World Health Organization (WHO), continues to be the most common cause of cancer deaths, with more than 2.2 million new cases in 2023. Nearly 85% of lung cancers are due to continued smoking, which is the main risk factor. Growing exposure to indoor air pollution and workplace carcinogens is also contributing to the prevalence of disease. The American Cancer Society also indicated that non-small cell lung cancer (NSCLC), such as adenocarcinoma, constitutes around 84% of all U.S. cases of lung cancer. Increased awareness and early screening initiatives, coupled with the expanding utilization of next-generation sequencing (NGS) for mutation identification, have improved the earlier treatment and diagnostic planning, which in turn continues to stimulate the use of new therapy options in the market.
Restraint
High Treatment Costs and Limited Accessibility Restraining the market growth.
The exorbitant price of metastatic lung adenocarcinoma therapy continues to be a major hindrance to patient access, especially in low- and middle-income countries. Sophisticated treatments like targeted therapies and immunotherapies are not only expensive. For example, AstraZeneca's Tagrisso (osimertinib) costs around USD15,000 a month, while Merck's Keytruda (pembrolizumab) can be over USD150,000 a year. Even in more affluent regions, healthcare reimbursement regulations are different, and thus, treatment is differentially available. An American Society of Clinical Oncology (ASCO) 2023 report reported that close to 20% of American lung cancer patients experience financial constraints in treatment affordability. Moreover, in developing economies, limited biomarker testing availability impinges on the uptake of personalized treatments. All these setbacks, in addition to increasing global healthcare spending, limit patient access to lifesaving drugs, which holds back market growth.
Opportunities
The growing advancements in biomarker-driven therapies present a significant opportunity in the metastatic lung adenocarcinoma treatment market.
Personalized medicine is revolutionizing cancer treatment, with targeted treatments such as EGFR, ALK, and KRAS inhibitors demonstrating better patient outcomes. Roche was approved by the FDA for Tecentriq Hybreza, a subcutaneous PD-(L)1 inhibitor, in 2024, significantly shortening administration time. In addition, Merck's Phase 3 trial of MK-1084, a KRAS G12C inhibitor, marks continued innovation in precision oncology. The expanding use of comprehensive genomic profiling and next-generation sequencing (NGS) allows oncologists to personalize therapy successfully. With an increase in clinical trials and partnerships between pharmaceutical companies and diagnostic firms, the incorporation of biomarker-based therapies is likely to improve survival rates and increase treatment options, offering a profitable opportunity for market expansion.
Challenges
One of the critical challenges in metastatic lung adenocarcinoma treatment is the emergence of resistance to targeted therapies.
EGFR, ALK, and KRAS inhibitors are highly effective at first, but most patients eventually develop acquired resistance and experience disease progression over time. For instance, research has indicated that close to 60% of EGFR-mutant NSCLC patients develop resistance to frontline osimertinib as a result of secondary mutations or bypass signaling pathways. This requires ongoing research into new-generation inhibitors and combination treatments. Furthermore, tumor heterogeneity complicates the accurate prediction of treatment response. AstraZeneca and Amgen are investing in new therapeutic strategies, but resistance is still challenging to overcome. Without resistance management breakthroughs, patients risk having few long-term treatment options, which is a major challenge for the industry in maintaining the prolonged efficacy of current therapies.
By Treatment
The chemotherapy segment dominated the metastatic lung adenocarcinoma treatment market with a 34.26% market share in 2023 because it has been the gold standard for years, especially among patients who do not have particular genetic mutations. Chemotherapy is still commonly prescribed because it can be used in a wide range of lung cancer subtypes and can effectively decrease tumor burden. It is also frequently combined with targeted therapies or immunotherapies to increase the effectiveness of treatment. The availability and relative affordability of chemotherapy over new medicines have further augmented its ascendancy, particularly where healthcare budgets are low. Irrespective of the breakthrough by targeted medicines and immunotherapeutics, chemotherapy is still the fundamental treatment of choice, even more so among end-stage patients as well as individuals who cannot undergo molecular-targeted medications.
Immunotherapy will be the fastest-growing segment during the forecast years because of its revolutionary role in lung cancer treatment. The launch of immune checkpoint inhibitors such as Merck's Keytruda (pembrolizumab) and Bristol-Myers Squibb's Opdivo (nivolumab) has dramatically enhanced survival rates among patients with metastatic lung adenocarcinoma. Immunotherapy boosts the patient's immune system to recognize and kill cancer cells, with a greater duration of action and fewer adverse effects than conventionally used chemotherapy. As patient selection criteria continue to evolve through research, combination regimens with chemotherapy and targeted agents further drive the acceptance of immunotherapy, positioning it as the most rapidly growing market in the forecast years.
By End Use
The hospitals segment dominated the metastatic lung adenocarcinoma market with around 66.35% market share in 2023 because of their holistic treatment process for cancer patients, from diagnosis to advanced level of treatment options and post-treatment care. Hospitals, mainly large oncology centers and tertiary care facilities, provide a multipronged style of cancer management, bringing under one umbrella chemotherapy, immunotherapy, targeted therapy, and radiotherapy. In addition, hospitals also have access to advanced diagnostic imaging and laboratory equipment to facilitate exact tumor profiling and tailored treatment regimens. Clinics of clinical trials and novel therapies also contribute to patient preference for treatment in hospitals. Additionally, reimbursement policies for healthcare also prefer hospital-based cancer treatment, and hence it becomes the most preferred option for several patients, particularly in developed parts of the world like North America and Europe.
The specialty clinics segment is anticipated to witness the fastest growth in the forecast period as a result of the rising demand for outpatient-based cancer care and personalized medicine. Specialty oncology clinics are more patient-friendly, with greater emphasis on targeted therapies and immunotherapy and fewer hospitalization stays. These clinics provide faster access to oncologists, cutting waiting times for starting treatment. Also, technological advancements in subcutaneous and oral cancer treatments like Roche's Tecentriq Hybreza, enabling quicker delivery outside of hospitals, are making specialist clinics increasingly feasible for the treatment of metastatic lung adenocarcinoma. An escalating number of partnerships between oncology centers and pharmaceutical firms to increase treatment availability, combined with the cost-effectiveness of such clinics, further contributes to the segment's swift growth, especially in developing markets.
North America dominated the metastatic lung adenocarcinoma treatment market with a 38.12% market share in 2023, owing to its strong established healthcare infrastructure, high adoption rate of innovative therapies, and high investment in cancer research. North America has a high concentration of major pharmaceutical firms like AstraZeneca, Merck, and Pfizer, which are focused on developing and marketing targeted therapies and immunotherapies. The U.S. Food and Drug Administration (FDA) has also been leading in the approval of innovative treatments like AstraZeneca's Tagrisso along with chemotherapy, which was approved in February 2024 under the FLAURA2 trial findings. The greater incidence of lung cancer due to smoking behavior and environmental factors pushes the demand for effective treatments further. Public and private healthcare expenditures also promote patients' access to new treatments, solidifying the leadership of North America in the market.
The Asia Pacific is experiencing the fastest expansion in the metastatic lung adenocarcinoma treatment market with a 12.68% CAGR, because of the growing incidence of lung cancer, augmenting healthcare investment, and improving access to more advanced treatments. China, Japan, and India are increasing their oncology infrastructure to treat cancer and introducing national screening programs to detect lung cancer at an earlier stage. There's also a high growth in clinical trials and regulatory approvals in the region, including China's fast-track nods for new-generation EGFR and ALK inhibitors. In addition, the increasing use of precision medicine and the option for cost-saving biosimilars are fueling market growth. Government efforts to subsidize the treatment of oncology and partnerships between international pharma companies and local biotech firms continue to spur the high development of the market for treating metastatic lung adenocarcinoma in Asia Pacific.
AstraZeneca (Tagrisso, Iressa)
Roche (Tarceva, Alecensa)
Merck & Co. (Keytruda, Lenvima)
Bristol-Myers Squibb (Opdivo, Yervoy)
Pfizer (Xalkori, Vizimpro)
Novartis (Zykadia, Mekinist)
Eli Lilly and Company (Cyramza, Alimta)
Johnson & Johnson (Rybrevant, Lazcluze)
Amgen (Lumakras, Vectibix)
Takeda Pharmaceutical Company (Alunbrig, Mobocertinib)
Boehringer Ingelheim (Giotrif, Vargatef)
Sanofi (Libtayo, Jevtana)
Daiichi Sankyo (Enhertu, Patritumab Deruxtecan)
Astellas Pharma (Xospata, Tarceva)
GlaxoSmithKline (Zejula, Jemperli)
Regeneron Pharmaceuticals (Libtayo, Zaltrap)
AbbVie (Rova-T, Imbruvica)
Clovis Oncology (Rubraca, Lucitanib)
Blueprint Medicines (Gavreto, Ayvakit)
BeiGene (Tislelizumab, Pamiparib)
Suppliers (These suppliers play a crucial role in the production, development, and supply chain of metastatic lung adenocarcinoma treatments, including biologics, small-molecule drugs, and targeted therapies.)
Lonza Group
WuXi AppTec
Catalent, Inc.
Samsung Biologics
Boehringer Ingelheim BioXcellence
Patheon (Thermo Fisher Scientific)
Samsung Bioepis
Fujifilm Diosynth Biotechnologies
AGC Biologics
Abzena plc
Recent Development
February 2024 – AstraZeneca's Tagrisso (osimertinib) with chemotherapy has been approved in the US to treat adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval followed the results of the FLAURA2 clinical trial, which showed that Tagrisso combined with chemotherapy lengthened median progression-free survival by almost nine months versus the standard of care.
April 2024 – Merck has started a Phase 3 clinical trial to explore MK-1084, a potential oral KRAS G12C inhibitor, in combination with KEYTRUDA (pembrolizumab) as initial treatment for some patients with metastatic non-small cell lung cancer. The study will evaluate the safety and efficacy of the combination regimen to determine whether it can enhance patient outcomes.
September 2024 – Roche reported that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor to be given as a subcutaneous (SC) injection in the U.S. This new form of administration makes it possible to give in about seven minutes, cutting infusion time significantly from the 30-60 minute intravenous (IV) infusion of Tecentriq (atezolizumab). Tecentriq Hybreza will be available for all the prior-approved IV indications in adult patients, such as some lung, liver, skin, and soft tissue cancers.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 4.35 billion |
| Market Size by 2032 | US$ 11.58 billion |
| CAGR | CAGR of 11.54% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Other) • By End Use (Hospitals, Specialty Clinics, Other) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | AstraZeneca, Roche, Merck & Co., Bristol-Myers Squibb, Pfizer, Novartis, Eli Lilly and Company, Johnson & Johnson, Amgen, Takeda Pharmaceutical Company, Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Astellas Pharma, GlaxoSmithKline, Regeneron Pharmaceuticals, AbbVie, Clovis Oncology, Blueprint Medicines, BeiGene, and other players. |
Ans: The Metastatic Lung Adenocarcinoma Treatment Market is expected to grow at a CAGR of 11.54% during 2024-2032.
Ans: The Metastatic Lung Adenocarcinoma Treatment Market was USD 4.35 billion in 2023 and is expected to Reach USD 11.58 billion by 2032.
Ans: The growing advancements in biomarker-driven therapies present a significant opportunity in the metastatic lung adenocarcinoma treatment market.
Ans: The “Chemotherapy” segment dominated the Metastatic Lung Adenocarcinoma Treatment Market.
Ans: North America dominated the Metastatic Lung Adenocarcinoma Treatment Market in 2023.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Metastatic Lung Adenocarcinoma (2023)
5.2 Prescription Trends for Metastatic Lung Adenocarcinoma Treatments (2023), by Region
5.3 Patient Volume Receiving Treatment, by Region (2020-2032)
5.4 Healthcare Spending on Metastatic Lung Adenocarcinoma Treatment, by Region (Government, Commercial, Private, Out-of-Pocket), 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Metastatic Lung Adenocarcinoma Treatment Market Segmentation, by Treatment
7.1 Chapter Overview
7.2 Chemotherapy
7.2.1 Chemotherapy Market Trends Analysis (2020-2032)
7.2.2 Chemotherapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2 Targeted Therapy
7.2.1 Targeted Therapy Market Trends Analysis (2020-2032)
7.2.2 Targeted Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2 Immunotherapy
7.2.1 Immunotherapy Market Trends Analysis (2020-2032)
7.2.2 Immunotherapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2 Radiation Therapy
7.2.1 Radiation Therapy Market Trends Analysis (2020-2032)
7.2.2 Radiation Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2 Other
7.2.1 Other Market Trends Analysis (2020-2032)
7.2.2 Other Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Metastatic Lung Adenocarcinoma Treatment Market Segmentation, by End User
8.1 Chapter Overview
8.2 Hospitals
8.2.1 Hospitals Market Trends Analysis (2020-2032)
8.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Specialty Clinics
8.3.1 Specialty Clinics Market Trends Analysis (2020-2032)
8.3.2 Specialty Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2020-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.2.4 North America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.2.5.2 USA Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.2.6.2 Canada Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.2.7.2 Mexico Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.1.5.2 Poland Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.1.6.2 Romania Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.2.4 Western Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.2.5.2 Germany Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.2.6.2 France Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.2.7.2 UK Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.2.8.2 Italy Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.2.9.2 Spain Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Healthcare Predictive Analytic Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.2.12.2 Austria Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.4.4 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.4.5.2 China Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.4.5.2 India Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.4.5.2 Japan Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.4.6.2 South Korea Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.2.7.2 Vietnam Healthcare Predictive Analytic Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.4.8.2 Singapore Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.4.9.2 Australia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.5.1.4 Middle East Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.5.1.5.2 UAE Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.5.2.4 Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.6.4 Latin America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.6.5.2 Brazil Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.6.6.2 Argentina Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.6.7.2 Colombia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by Treatment (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10. Company Profiles
10.1 Takeda Pharmaceutical Company
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Amgen
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Johnson & Johnson
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Eli Lilly and Company
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Novartis
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Pfizer
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Bristol-Myers Squibb
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Merck & Co.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Roche
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 AstraZeneca
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusio
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Treatment
Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Other
By End Use
Hospitals
Specialty Clinics
Other
Request for Segment Customization as per your Business Requirement: Segment Customization Request
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Bionic Eye Market size was valued at USD 254.10 Million in 2023 and is expected to reach USD 810.08 Million by 2032 and grow at a CAGR of 13.77% over the forecast period 2024-2032.
The Cryoablation Devices Market size will reach $1295.34 Mn by 2032, was valued at $489.53 Mn in 2023 & growing at a CAGR of 10.26% over 2024-2032.
The Urinary Drainage Bags Market size was valued at USD 1.80 Billion in 2023, expected to reach USD 2.64 Billion by 2032, grow at a CAGR of 4.38%.
Meningitis Diagnostic Testing Market was valued at USD 116.66 million in 2023 and is expected to reach USD 158.47 million by 2032, growing at a CAGR of 3.50% from 2024-2032.
The Healthcare Mobility Solutions Market Size was valued at USD 150.19 billion in 2023, and is expected to reach USD 1143.40 billion by 2032, and grow at a CAGR of 25.3% over the forecast period 2024-2032.
The Monoclonal Antibody Therapy Market size was valued at USD 87.8 Bn in 2023 and is expected to reach USD 230.38 Bn by 2031 with a growing CAGR of 12.8% Over the Forecast Period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
